| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2002.09.091 |
| P8608 | Fatcat ID | release_nkg3gvzogbhw3ntapzbwzqbfh4 |
| P698 | PubMed publication ID | 12065560 |
| P50 | author | Pierre Laurent-Puig | Q37067941 |
| Christophe Rosty | Q51118591 | ||
| Jean Robert Delpero | Q59677704 | ||
| P2093 | author name string | Gérard Milano | |
| Maurice Chazal | |||
| Nicolas Magné | |||
| Jean-François Seitz | |||
| Christian Letoublon | |||
| Denis Pezet | |||
| Emmanuel Chamorey | |||
| Patricia Formento | |||
| Jean-Louis Formento | |||
| Mireille Francoual | |||
| Nicole Renée | |||
| André Bourgeon | |||
| Marie-Christine Etienne | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| colorectal cancer | Q188874 | ||
| chemotherapy | Q974135 | ||
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 2832-2843 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses | |
| P478 | volume | 20 |
| Q31080865 | A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer |
| Q33424920 | A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors |
| Q34349053 | Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy |
| Q43893904 | Associations of polymorphisms of folate cycle enzymes and risk of breast cancer in a Brazilian population are age dependent |
| Q37623502 | Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases |
| Q60629772 | Cancer colorectal : altérations moléculaires pronostiques |
| Q80510550 | Cancers of the large bowel and hepatobiliary tract |
| Q81086290 | Cancers of the large bowel and hepatobiliary tract |
| Q38002127 | Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. |
| Q35579927 | Colon Cancer and Genetic Variation in Folate Metabolism: The Clinical Bottom Line |
| Q43048728 | Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas |
| Q35773077 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. |
| Q35666148 | ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer |
| Q36142392 | Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase |
| Q54571689 | Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome. |
| Q27863368 | G>C SNP of thymidylate synthase with respect to colorectal cancer |
| Q35731144 | Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years |
| Q91768395 | High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma |
| Q60930855 | Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis |
| Q35128610 | Implications of Genetic Testing in the Management of Colorectal Cancer |
| Q38075848 | Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review |
| Q41608501 | Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. |
| Q33245747 | Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance |
| Q36859220 | Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy |
| Q46765481 | Looking for the right drug for the right patient: a tale of old drugs and new pathways |
| Q84843811 | Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? |
| Q38247982 | MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. |
| Q33337970 | Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker |
| Q46755685 | Molecular biology in clinical cancer research: the example of digestive cancers |
| Q33682949 | Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study |
| Q47794376 | Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor |
| Q45959713 | P53 Arg72Pro polymorphism in gastric cancer patients. |
| Q30336665 | Pharmacogenetic aspects in treatment of colorectal cancer – an update |
| Q37235638 | Pharmacogenetics in colorectal cancer: a systematic review |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q47324233 | Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). |
| Q90635210 | Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer |
| Q44458788 | Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer |
| Q33320579 | Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy |
| Q34099389 | Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy |
| Q35073360 | Recent advances in the pharmacological treatment of colorectal cancer |
| Q46466609 | Relationship between thymidylate synthase (TS) genotype and TS expression: a tissue microarray analysis of colorectal cancers |
| Q35139963 | Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? |
| Q45073488 | Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients |
| Q46187727 | TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials |
| Q34837030 | The impact of pharmacogenomics on gastrointestinal cancer therapy |
| Q40183302 | The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer |
| Q40095644 | The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors |
| Q38796384 | Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity |
| Q45148168 | Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. |
| Q37277642 | Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. |
| Q81481891 | Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer |
| Q44101054 | Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy |
| Q36610609 | Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma. |
| Q33395508 | Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine |
| Q47741359 | Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment |
| Q38181431 | Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. |
| Q42600675 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer |
| Q27851574 | UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy |
Search more.